Product image of Lipocomb (Ezetimibe, Rosuvastatin Zinc) supplied by GNH India

Lipocomb

Active Ingredient:
Ezetimibe, Rosuvastatin Zinc
Origin:
EU

Lipocomb (Ezetimibe, Rosuvastatin Zinc)

Ezetimibe, the active ingredient in Lipocomb, is a cholesterol absorption inhibitor presented as a tablet for oral use. It reduces intestinal cholesterol absorption, helping to lower LDL‑cholesterol in adults with primary hypercholesterolemia or mixed dyslipidemia. The combination also includes rosuvastatin zinc, a potent HMG‑CoA reductase inhibitor that further decreases hepatic cholesterol synthesis and up‑regulates LDL receptors, enhancing overall lipid control.

GNH India supplies Lipocomb as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. Our distribution network ensures consistent quality and regulatory compliance across all markets.

Manufacturer / TM Owner

Egis Pharmaceuticals Plc

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Lipocomb, a fixed‑dose combination of ezetimibe and rosuvastatin, is used to manage disorders of lipid metabolism.

  • Hypercholesterolemia: lowers LDL‑cholesterol and total cholesterol levels.
  • Mixed dyslipidemia: improves LDL, triglycerides and HDL profiles.
  • Primary prevention of cardiovascular events: reduces risk of myocardial infarction and stroke in high‑risk patients.
  • Heterozygous familial hypercholesterolemia: provides additional LDL‑cholesterol reduction when statin monotherapy is insufficient.

How It Works

  • Ezetimibe selectively inhibits the intestinal Niemann‑Pick C1‑like 1 (NPC1L1) transporter, blocking the uptake of dietary and biliary cholesterol. Rosuvastatin zinc competitively inhibits HMG‑CoA reductase, the key enzyme in hepatic cholesterol synthesis, leading to up‑regulation of LDL receptors on hepatocytes. The combined effect reduces circulating LDL‑cholesterol more than either agent alone and improves overall lipid profile. This dual inhibition provides additive LDL‑cholesterol lowering and contributes to plaque stabilization.

Side Effects

Lipocomb may cause a range of adverse reactions, varying in frequency and severity.

Common Side Effects

  • Headache: mild to moderate headache reported in clinical use.
  • Myalgia: muscle aches without significant CK elevation.
  • Abdominal discomfort: nausea, dyspepsia or flatulence.
  • Elevated liver enzymes: transient increase in ALT/AST.
  • Diarrhea: loose stools.
  • Fatigue: general tiredness.

Serious or Rare Side Effects

  • Myopathy/Rhabdomyolysis: severe muscle breakdown, especially with high‑dose statins.
  • Severe hepatic injury: marked elevation of transaminases or jaundice.
  • Allergic reactions: rash, pruritus or angioedema.

Precautions & Warnings

Before prescribing Lipocomb, clinicians should consider several precautionary measures to ensure patient safety.

  • Liver function monitoring: assess baseline ALT/AST and repeat periodically.
  • Renal impairment: adjust therapy in severe kidney disease.
  • Drug interactions: review concomitant medications that affect statin metabolism.
  • Pregnancy and lactation: avoid use unless benefits outweigh risks.
  • Muscle disorders: discontinue if signs of myopathy appear.
  • Store at ambient temperature: keep tablets in original container, protect from moisture and light.

Avoid Interactions

Lipocomb can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

  • Strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole): increase rosuvastatin exposure, risk of myopathy.
  • Cyclosporine: markedly raises rosuvastatin levels, contraindicated.
  • Gemfibrozil: enhances statin‑related muscle toxicity.
  • Antacids containing aluminum/magnesium: may reduce ezetimibe absorption.

Moderate Interactions (Monitor Closely)

  • Warfarin: may increase INR, monitor coagulation.
  • Niacin: additive effect on liver enzymes.
  • Other fibrates (excluding gemfibrozil): monitor for muscle symptoms.

Frequently Asked Questions

Lipocomb is a prescription tablet that combines ezetimibe and rosuvastatin zinc to lower elevated cholesterol levels. It is indicated for adults with primary hypercholesterolemia, mixed dyslipidemia, and for the primary prevention of cardiovascular events in patients at increased risk.

Ezetimibe blocks the Niemann‑Pick C1‑like 1 (NPC1L1) transporter located on the brush border of the small intestine. By inhibiting this transporter, ezetimibe reduces the absorption of dietary and biliary cholesterol, leading to lower circulating LDL‑cholesterol.

The dosage of Lipocomb is individualized by the prescribing clinician based on the patient’s lipid profile, cardiovascular risk, and tolerability. The prescriber determines the appropriate strength and frequency according to current clinical guidelines.

Safety of Lipocomb during pregnancy or lactation has not been established. It should be used only if the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made by a qualified healthcare professional.

To order Lipocomb, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Lipocomb offers a dual mechanism—cholesterol absorption inhibition by ezetimibe and synthesis inhibition by rosuvastatin—providing greater LDL‑cholesterol reduction than a statin alone. This can be advantageous for patients who need additional lipid control without escalating statin dose, while maintaining a convenient single‑tablet regimen.

Store Lipocomb tablets at ambient temperature, preferably below 25 °C. Keep the tablets in the original packaging, protect them from moisture and direct light, and ensure the container is tightly closed to maintain product stability.

Lipocomb is taken orally, usually once daily, with or without food. The tablet should be swallowed whole with a glass of water. Patients should follow the dosing schedule prescribed by their healthcare provider.

The most serious risks include myopathy or rhabdomyolysis, which can present as severe muscle pain, weakness, and elevated creatine kinase, and serious hepatic injury, indicated by marked increases in liver enzymes or jaundice. Prompt medical evaluation is required if these symptoms occur.

Lipocomb is contraindicated in patients with known hypersensitivity to ezetimibe, rosuvastatin, or any excipients in the tablet. It should also be avoided in individuals with active liver disease, unexplained persistent elevations of transaminases, or in those taking contraindicated medications such as strong CYP3A4 inhibitors or cyclosporine.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Ezetimibe, Rosuvastatin Zinc

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT